Hot Investor Mandate: Europe Investment Firm Actively Seeking Innovative Therapeutics that Address Unmet Need, with Focus on Europe-Based Companies

14 Feb

A leading independent venture capital firm in Western Europe provides private equity financing to early- and mid-stage human healthcare and life science companies. The firm has raised two funds, and generally allocates $4-7M (in equity) per company, always co-investing with other specialized investors and during the whole life of the investment. The firm is currently prioritizing opportunities in Europe.

The firm invests in innovative therapeutics. The firm focuses on indications with a clear unmet need, and prefers to invest in opportunities that have realistic exit potential in 2-3 years. In case of niche/orphan indications, the potential market share should be significant and realistic. The firm invests in small molecules, biologics and advanced therapies. At minimum, the product should have solid animal data.

The firm looks for a cohesive management team with a proven track record, including relevant business experience and top-notch scientific know-how. The firm requires a board seat in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: